TSC2 and neoplasm: In prior preclinical studies, we used two TSC2 tumor models to demonstrate that while both the rapamycin analog, CCI-779, and IFN-g are effective in reducing tumor growth, rapamycin is more effective than CCI-779, and effective rapamycin doses are absorbed after topical administration [18-21].